These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 26427750)

  • 1. Anti-inflammatory strategies in the treatment of schizophrenia.
    Andrade C
    Expert Rev Clin Pharmacol; 2016; 9(2):161-3. PubMed ID: 26427750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond.
    Meyer U; Schwarz MJ; Müller N
    Pharmacol Ther; 2011 Oct; 132(1):96-110. PubMed ID: 21704074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonsteroidal anti-inflammatory drugs and 5-HT₃ serotonin receptor antagonists as innovative antipsychotic augmentation treatments for schizophrenia.
    Andrade C
    J Clin Psychiatry; 2014 Jul; 75(7):e707-9. PubMed ID: 25093487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sertindole for the treatment of schizophrenia.
    Azorin JM; Kaladjian A; Fakra E; Adida M
    Expert Opin Pharmacother; 2010 Dec; 11(18):3053-64. PubMed ID: 21080854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis.
    Sommer IE; de Witte L; Begemann M; Kahn RS
    J Clin Psychiatry; 2012 Apr; 73(4):414-9. PubMed ID: 22225599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of cognitive dysfunction in schizophrenia.
    Peuskens J; Demily C; Thibaut F
    Clin Ther; 2005; 27 Suppl A():S25-37. PubMed ID: 16198199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: an 8-week, double-blind, randomized add-on two-center trial.
    Ritsner MS; Bawakny H; Kreinin A
    Psychiatry Clin Neurosci; 2014 Jun; 68(6):432-40. PubMed ID: 24548129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging Treatments in Schizophrenia: Highlights from Recent Supplementation and Prevention Trials.
    Brown HE; Roffman JL
    Harv Rev Psychiatry; 2016; 24(2):e1-7. PubMed ID: 26954600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The question of pro-inflammatory immune activity in schizophrenia and the potential importance of anti-inflammatory drugs.
    Arolt V; Ambrée O
    Mod Trends Pharmacopsychiatry; 2013; 28():100-16. PubMed ID: 25224894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmentation of olanzapine in treatment-resistant schizophrenia.
    Zink M
    J Psychiatry Neurosci; 2005 Nov; 30(6):409-15. PubMed ID: 16327874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential of Oxytocin in the Treatment of Schizophrenia.
    Shilling PD; Feifel D
    CNS Drugs; 2016 Mar; 30(3):193-208. PubMed ID: 26895254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopaminergic deficit and the role of amisulpride in the treatment of schizophrenia.
    Kasper S
    Int Clin Psychopharmacol; 2002 Dec; 17 Suppl 4():S19-26. PubMed ID: 12685918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glutamatergic agents for schizophrenia: current evidence and perspectives.
    Zink M; Correll CU
    Expert Rev Clin Pharmacol; 2015 May; 8(3):335-52. PubMed ID: 25916667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials.
    Ardizzone I; Nardecchia F; Marconi A; Carratelli TI; Ferrara M
    Psychopharmacol Bull; 2010; 43(2):45-66. PubMed ID: 21052042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia.
    Tandon R; Belmaker RH; Gattaz WF; Lopez-Ibor JJ; Okasha A; Singh B; Stein DJ; Olie JP; Fleischhacker WW; Moeller HJ;
    Schizophr Res; 2008 Mar; 100(1-3):20-38. PubMed ID: 18243663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjunctive use of anti-inflammatory drugs for schizophrenia: A meta-analytic investigation of randomized controlled trials.
    Cho M; Lee TY; Kwak YB; Yoon YB; Kim M; Kwon JS
    Aust N Z J Psychiatry; 2019 Aug; 53(8):742-759. PubMed ID: 30864461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Heinrichs RW
    Arch Gen Psychiatry; 2007 Jun; 64(6):631-2. PubMed ID: 17548745
    [No Abstract]   [Full Text] [Related]  

  • 20. Polypharmacy in schizophrenia.
    Zink M; Englisch S; Meyer-Lindenberg A
    Curr Opin Psychiatry; 2010 Mar; 23(2):103-11. PubMed ID: 20051861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.